Ben Lin Email & Phone Number

Boston, Ma, Us

Paris, France, Fr

R&D leader driving development of several I&I early stage assets, including:+ SAR445399, an anti-IL1R3 mAb currently in Phase 1+ SAR446422, an anti-CD28/OX40 bispecific mAb currently in Phase1

Paris, France, Fr

+ Ensure team execution for excom-level meetings, providing guidance for other team members and ad hoc leadership for priority assessments or workstreams+ Oversee team efforts on program stage gates to provide strategic support for complex trade-offs+ Advance PDR analytics and digitalization to improve team efficiency and senior management access+ Train team members and refine analytical tools to deliver consistent, high quality PDR team output

Paris, France, Fr

+ Global coordinator for 2018 and 2019 portfolio review, covering 60+ development projects across 7 therapeutic areas+ Developed analytics and methodology currently used by senior management for R&D pipeline decision-making+ Represented portfolio function at major governance reviews (TA, R&D, and excom level)+ Improved quality of project assessments by facilitating cross-functional debate and challenging key assumptions+ Day-to-day responsibility for I&I and Rare Diseases projects, coordinating valuation work between project teams and global functions+ Held similar responsibility for Oncology and Neurology TAs in previous PFR cycles

Boston, Ma, Us

+ Led case teams in 40+ engagements in the life science, medical device, and healthcare sectors+ Supported sellers and potential buyers in transactions across several sectors, including over $2B in completed dealsSelect examples from life science engagements:+ In-depth asset evaluation and forecasting to determine licensing and transaction decisions across a wide range of therapeutic areas (including cardiovascular, dermatology, gastrointestinal, oncology, ophthalmology, respiratory, rheumatology, women’s health)+ Portfolio revenue forecasts to support operational planning, royalty financing and transactions+ Pipeline review and prioritization for the oncology franchise of a mid-sized biopharma+ Strategic response of a large biopharma to European healthcare cost containment trends+ Market assessment and growth strategy for the CNS franchise of a large biopharma+ Disease area prioritization and growth strategy for a respiratory-focused biopharma+ Geographic prioritization and international expansion strategy for an orphan drug leader+ Workshop facilitation and support for a global franchise conference of a large biopharma+ Commercial due diligences on contract research organizations and contract manufacturing organizations to support private equity and corporate transactionsMedtech, healthcare and retail experience, select examples:+ Trends analysis and strategic implications for the European medtech market+ Adjacency growth strategy and opportunity assessment in U.S. telemedicine+ Commercial due diligences on medical devices, radiation oncology centers, specialty food manufacturers, and a low-cost retail chain

+ Refined market models and investment theses for over 40 small and mid cap biotechnology companies+ Wrote initiation reports and proposed stock valuation for 3 companies in oncology, pain, and orphan drug space

Phd, Chemical Engineering Practice

Mba

Bs, Biomedical Engineering And Chemical Engineering